Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee proce
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)...  Digirad Corporation (Nasdaq: DRAD) today announced that it has ... PDII ), a healthcare commercialization services company, responding to ... company.  Digirad calls upon PDI to ... to operate in the ordinary course of business and ... debt, on acquisitions or other extraordinary transactions. Digirad believes ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... economy recovery continues to lag, employers are looking for ... costs. Running counter to these goals, independent drugstores are ... to save money by offering lower cost home delivery ... (PCMA) said today. "As the economic recovery ...
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
Cached Medicine Technology:As Economic Recovery Sputters, Independent Drugstores Shouldn't Shoulder Employers With Higher Costs 2Amerigroup Foundation Presents Grant to Rx Partnership 2
(Date:10/31/2014)... (PRWEB) October 31, 2014 Springboard ... for its small scale BioPro™ biodiesel processors, announced ... will further improve the performance and efficiency of ... GL95/MC12/BD380 trio will recover more than ... in with the glycerin by-product produced while making ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org reveals that ... suffered from Alzheimer's disease. , In fact, Alexander Lynch ... disease. His father pointed a gun and shot him during ... author of this method understood that he needed to do ... program is based on years of research. The author of ...
(Date:10/31/2014)... 2014 At the start of 2014, ... escaping carbon monoxide poisoning in their homes. Now, as ... one family-owned, Missouri-based heating and cooling company is taking ... families start the home heating season with the assurance ... , Beginning Nov. 1, 2014, E and Q Heating ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Surgery for low ... where in the United States you live, a new ... experience low back pain at some point in their ... professional medical care for a spine problem," co-author Brook ... Clinical Practice, said in a college news release. ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... Congratulate Players, MCKINNEY, Texas, Nov. 10 ... cards last night following the,Nationwide Tour Championship at ... PGA TOUR,s newest official marketing,partner, hosted a celebratory ... for their achievement., "This class adds to ...
... to spur cancer,s growth could actually hinder rather than ... the University of California, San Diego. , The findings ... strangling its blood supply have been disappointing when used ... combined with traditional chemotherapy. , Despite their rapid progression, ...
... Cancer cells are already stressed by the fast pace they require ... just may kill them. , "Think about an assembly line in ... Dr. Kapil Bhalla, director of the Medical College of Georgia ... workers to keep going. Some of them fall out, some get ...
... Pennsylvania Facilities Meet Federal Standards, HARRISBURG, Pa., ... reports today showing that all of the 76,mammography ... this year,are operating within the guidelines set forth ... inspects each of Pennsylvania,s approximately 400 certified,mammography facilities ...
... to present results from Phase 1/2 Clinical Trial of,Perifosine ... 2008 at 8:30am, NEW YORK, Nov. 10 ... data from its Phase 1/2 clinical,trial of KRX-0401 (perifosine) ... Annual Meeting of the American Society of Hematology,(ASH), to ...
... NEW YORK, Nov. 10 The American Society ... (RPR) to educate the public on the interventional ... use to,relieve pain., Founded in 1998, ASIPP ... all interventional pain physicians. ASIPP members are board,certified ...
Cached Medicine News:Health News:Top 25 Nationwide Tour Players Earn PGA TOUR Cards for 2009 Season 2Health News:Top 25 Nationwide Tour Players Earn PGA TOUR Cards for 2009 Season 3Health News:Tumors grow faster without blood-supply promoting molecule 2Health News:Researchers aim to over-stress already taxed mantle cell lymphoma cells 2Health News:Researchers aim to over-stress already taxed mantle cell lymphoma cells 3Health News:DEP Releases Third Quarter Mammography Inspections 2Health News:DEP Releases Third Quarter Mammography Inspections 3Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 2Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 3Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 4Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 5Health News:Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology 6Health News:Rubenstein Public Relations to Launch National Campaign for The American Society of Interventional Pain Physicians 2
For use with E0828 needle and gouge set and E0828 C handle. Straight gouge shape tip. Polished finish. Most popular size or model....
Set consists of one each:E0824 A replacement burr set. E0824 B handle....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
Medicine Products: